Published in Transplantation on April 15, 1996
Pilot Trial for Implementation of a MPA PK Monitoring Strategy (MPA) | NCT00187915
A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation (1999) 1.14
Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol (2006) 1.06
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int (2009) 1.03
Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol (2006) 1.02
Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol (2005) 1.00
[Systemic immunosuppressives after penetrating keratoplasty]. Ophthalmologe (2007) 0.99
Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol (2008) 0.99
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant (2009) 0.97
Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol (2003) 0.95
Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol (2008) 0.94
Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol (2005) 0.93
Management of ANCA-associated vasculitis: Current trends and future prospects. Ther Clin Risk Manag (2010) 0.93
High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol (2005) 0.89
Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation. Am J Transplant (2009) 0.89
Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond) (2011) 0.88
Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunosuppressants: interventional case series. Int Ophthalmol (2009) 0.86
Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol (2010) 0.86
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol (2005) 0.85
Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant (2015) 0.84
Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol (2010) 0.84
Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol (2003) 0.84
A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci (2011) 0.83
Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen. Int Immunopharmacol (2011) 0.83
The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. J Am Soc Nephrol (2010) 0.82
Antibody induction therapy in adult kidney transplantation: A controversy continues. World J Transplant (2012) 0.81
Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol (2006) 0.81
[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z Rheumatol (2013) 0.80
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int (2014) 0.80
Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clin Mol Hepatol (2014) 0.80
A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients. Ann Surg Treat Res (2014) 0.80
Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis. Pharmaceuticals (Basel) (2013) 0.79
Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet (2015) 0.79
Ulcerative colitis after renal transplantation: A case report and review of literature. Indian J Nephrol (2011) 0.78
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag (2009) 0.78
Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int (2016) 0.78
Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient. Clin Exp Nephrol (2008) 0.76
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus]. Z Rheumatol (2007) 0.76
Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability. Ther Clin Risk Manag (2009) 0.76
Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. Clin Transplant (2012) 0.76
Mycophenolate Mofetil Study. Transplantation (1997) 0.76
Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. J Zhejiang Univ Sci B (2005) 0.76
Peripheral Lymphocyte Response to Mycophenolic Acid In Vitro and Incidence of Cytomegalovirus Infection in Renal Transplantation. Cell Med (2013) 0.75
The influence of mycophenolate mofetil and azathioprine on the same cadaveric donor renal transplantation. J Korean Med Sci (2005) 0.75
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients. Int J Nephrol Renovasc Dis (2010) 0.75
A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol (1998) 0.75
Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Eurasian J Med (2009) 0.75
Immunosuppression strategies after liver transplantation: a single centre experience in 57 liver transplant recipients. Indian J Surg (2008) 0.75
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol (2016) 0.75
West Meets East. Kidney Dis (Basel) (2015) 0.75
Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry. Clin Transplant (2012) 0.75
Early corticosteroid withdrawal regimen in a living donor kidney transplantation program. Indian J Nephrol (2014) 0.75
Mycophenolate mofetil-induced oral ulcerations in solid organ transplant recipients: A report of 3 cases. JAAD Case Rep (2015) 0.75
Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis. BMC Infect Dis (2015) 0.75
Renal Transplantation: Experience at a Single Centre. Med J Armed Forces India (2011) 0.75
Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. J Korean Med Sci (2010) 0.75
Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic Inflamm Infect (2011) 0.75
Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study. BMJ Open (2014) 0.75
Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study. J Nephropathol (2017) 0.75
Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure. Eur J Clin Pharmacol (2007) 0.75